Navigating the United States, Japan, Canada, European Union, South Korea, Australia and India Landscape of Dietary Supplement Regulation and Quality Assurance

Introduction: The Evolving World of Dietary Supplements

The global wellness and health sector has experienced a significant increase in both the consumption and accessibility of nutraceuticals and dietary supplements. These products are generally defined as concentrated nutrient sources, including vitamins and minerals, or other compounds that exert nutritional or physiological effects. They are usually offered in various dosage forms such as pills, capsules, tablets, or liquids, and are designed to enhance the regular diet [1]. The terminology used to describe these products, however, is far from uniform across international borders. In the United States, what is defined as a dietary supplement may be known as a natural health product (NHP) in Canada, a complementary or herbal medicine in Australia, or a food supplement in the European Union. This definitional divergence underscores a foundational challenge: the absence of a global harmony on how this product category is defined [2].

Nutraceuticals, while often grouped with dietary supplements, are typically distinguished by their purported therapeutic effects that extend beyond basic nutrition. Consumers frequently perceive them as safer alternatives to conventional pharmaceuticals, contributing to their growing popularity [3]. This perception, coupled with increasing public interest in disease prevention and health promotion, has fuelled substantial market expansion. The global market for dietary supplements was estimated to be around USD 178 billion in 2023, with projections indicating it will grow to USD 239.4 billion by 2028 [4]. This expansion is further amplified owing to rise in online cross-border shopping, which introduces additional complexities in regulatory oversight [4]. For instance, recent data indicates that in 2023, 80% Korean households made purchase of functional foods at least once, and half of the Australian population used complementary medicines in 2017 [4].

The prime aim of the report is to deliver a comprehensive review of the diverse regulatory frameworks governing dietary supplements, the application of Good Manufacturing Practices (GMP), and the persistent challenges concerning product quality and safety across key international jurisdictions, including the United States, Japan, Canada, European Union, South Korea, and Australia. By examining these multifaceted aspects, the report aims to illuminate the complexities and inconsistencies inherent in current global oversight mechanisms and to propose strategic approaches for enhancing product quality and consumer safety worldwide.

The existence of multiple terms for similar products across different countries, coupled with the absence of a global consensus on their definition, creates a significant challenge for both regulatory bodies and industry stakeholders. This fragmentation contributes to a lack of clarity in determining which regulatory frameworks apply to specific products [2]. Consequently, the similar product might be classified differently—as a food in one Member State and a medicine in another—leading to "borderline issues" that complicate market entry and compliance for manufacturers operating internationally [5]. This inconsistency can inadvertently encourage regulatory arbitrage, where companies may seek the path of least regulatory resistance, potentially compromising consumer protection. The increasingly globalized nature of the marketplace, where products are consumed worldwide, amplifies the need for harmonized global quality standards [6]. Without such harmonization in definitions and classification, establishing universal quality and safety standards becomes inherently difficult, directly contributing to the challenges of adulteration and inconsistent product quality that transcend national borders. This also impedes the ability to effectively track and respond to adverse events on a global scale [7].

Global Regulatory Frameworks for Dietary Supplements

The regulatory framework governing dietary supplements and nutraceuticals differs markedly from one country to another, reflecting diverse approaches to balancing consumer safety, product efficacy, and market innovation.

United States (US): FDA and 21 CFR Part 111

In the United States, the “Food and Drug Administration (FDA)” oversees the regulation of dietary supplements. Nevertheless, its regulatory approach mainly functions through a post-market surveillance system, as opposed to necessitating pre-market approval similar to that of pharmaceutical drugs. This regulatory structure was instituted by the “Dietary Supplement Health and Education Act (DSHEA)” of 1994. According to DSHEA, manufacturers are not required to submit fundamental product information to the FDA or evidence of efficacy before marketing their products. Consequently, the burden falls on the FDA to demonstrate that a product or ingredient is unsafe before it can restrict its use or mandate a recall [8].

A cornerstone of quality assurance in the US dietary supplement industry is compliance with “Current Good Manufacturing Practices (cGMPs)”, as stipulated in 21 CFR Part 111. These regulations outline the minimum requirements for the packaging, manufacturing, labelling, or holding procedures of dietary supplements required to maintain the product quality. Manufacturers bear the responsibility for establishing quality specifications for all ingredients, components, and finished products, and for verifying that these specifications are consistently met. The cGMPs encompass a broad range of operational controls, including personnel qualifications, the sanitation of physical plants and grounds, the appropriate design and maintenance of equipment, robust production and process controls, comprehensive quality control operations, and meticulous record-keeping. The inclusion of "current" in cGMP signifies an ongoing commitment to adopting the highest available quality standards and leveraging up-to-date systems and technologies.

The US regulatory model, with its primary reliance on post-market surveillance, presents inherent safety challenges. The fact that manufacturers are not required to submit efficacy evidence or basic product information to the FDA prior to marketing means that products can enter the market without rigorous upfront vetting. The responsibility of providing evidence lies with the regulator to establish the lack of safety before taking action creates a situation where potentially unsafe or ineffective products may remain available to consumers for extended periods, leading to potential harm before regulatory intervention occurs. This is particularly concerning given reports of over 15,000 adverse health events, including 339 deaths and nearly 4,000 hospitalizations, linked to supplements reported to the FDA's system between 2004 and 2013 [8]. This fundamental difference in regulatory philosophy, compared to the mandatory pre-market approval for pharmaceuticals, establishes a systemic vulnerability. It allows for a market that could be saturated with products whose safety and efficacy have not been thoroughly assessed upfront, thereby transferring the risk burden from manufacturers to consumers and the public health system. This necessitates substantial post-market enforcement efforts by the FDA [9].

European Union (EU): Harmonization and National Divergence

For European Union region, supplements (food) are regulated as foods, primarily under the overarching General “Food Law Regulation (EC) No 178/2002” and specifically Directive 2002/46/EC. While harmonized legislation governs minerals and vitamins and their sources (mentioned in Annex I and II of “Directive 2002/46/EC”), the regulation of "other substances," such as botanicals, often falls under national rules or other specific EU legislation like the Novel Foods Regulation (EC) No 2015/2283 [10].

The “European Food Safety Authority (EFSA)” plays a vital role by bringing forth scientific opinions to support the European Commission's evaluations, particularly concerning novel food applications and the establishment of tolerable upper intake levels (ULs) for micronutrients [1]. Furthermore, the “Hazard Analysis and Critical Control Points (HACCP)” system is a legally mandated standard for food producers, including those manufacturing dietary supplements, ensuring a robust food safety management system basis hazard analysis and the identification of critical control points [11].

Despite these EU-level legislative efforts, significant national differences persist, leading to considerable challenges in harmonization and mutual recognition. These disparities often result in "numerous trade barriers" and situations where the same product may be classified differently (e.g., as a food or a medicine) across various Member States [5]. There is currently no common EU-level positive list for permitted botanicals, meaning an ingredient allowed in one country might be prohibited in another, contributing to an "unfulfilled" regulatory landscape [6]. The absence of a dedicated nutrivigilance system at the EU level is also recognized as a significant gap in post-market surveillance [12].

The incomplete harmonization within the EU creates internal market friction and inconsistent consumer protection. The reliance on national rules for non-vitamin/mineral ingredients means that despite being part of a single market, consumers may encounter vastly different levels of product access and safety protection depending on their Member State. This regulatory patchwork can be exploited through "dishonest market practices," where entities may leverage notification procedures to keep questionable products on the market despite potential non-compliance [12]. The EU's ongoing struggle to achieve full harmonization, despite its stated objectives, demonstrates the inherent complexities in regulating a diverse product category across multiple sovereign states. This persistent divergence not only affects market efficiency but directly compromises the principle of consumer protection by fostering an uneven playing field for safety and quality standards across the Union, underscoring the critical need for further harmonization efforts.

Japan: Multi-tiered Health Food System

Japan employs a multi-tiered regulatory system for "health foods," primarily overseen by the “Ministry of Health, Labor, and Welfare (MHLW)”. This system distinguishes between "so-called health foods," Foods with Health Claims (FHCs), and pharmaceutical products.

The FHC system is a key component, comprising three categories:

• Foods for Specified Health Uses (FOSHU): This product category requires official approval from the MHLW. This approval process involves a rigorous examination of safety by the Food Safety Commission and an evaluation of efficacy by the Pharmaceutical Affairs and Food Sanitation Council [13]. FOSHU products are permitted to make specific structure/function claims [14].
• Foods with Function Claims (FFC): Introduced in 2015, FFCs operate under a notification system rather than requiring pre-market approval. Their efficacy claims must be substantiated through systematic reviews of functional components, often based on clinical trial research.
• Foods with Nutrient Function Claims (FNFC): For FNFCs, labels can be freely used provided the product adheres to established minimum and maximum daily consumption standards for standardized vitamins and minerals [13].

The MHLW sets general requirements and standards for all food products, including imports, with a strong emphasis on ingredient and manufacturing standards. Historically, Good Manufacturing Practices (GMPs) were not mandatory for "so-called health foods" and FOSHUs, operating on a voluntary basis [15]. However, a significant policy shift will make GMPs mandatory for FFCs starting September 2026 [15]. The “Japan Health Food & Nutrition Food Association (JHNFA)” plays a supportive role by operating a voluntary GMP certification program and a third-party safety certification program, both aligned with MHLW guidelines [16].

Japan's regulatory evolution demonstrates a gradual adaptation to market dynamics and public health incidents. The co-evolution of regulations with industry development, aimed at enthusiastically balancing risk and benefit, is evident. Key milestones, such as the introduction of the FFC system and the "Beni-koji (red yeast rice) contamination incident in 2024," have prompted adjustments in this balance. The decision to mandate GMPs for FFCs, particularly following a contamination incident, suggests that voluntary industry standards, while valuable, were ultimately deemed insufficient to guarantee public safety in a rapidly expanding market. This pattern reflects a common regulatory phenomenon where adverse events act as catalysts for the implementation of stricter, legally binding controls, shifting from industry self-regulation to governmental mandates. Japan's experience underscores the inherent tension in balancing industry innovation with robust consumer protection, and the critical need for more anticipatory regulatory science to prevent, rather than merely react to, public health crises in the dietary supplement sector. This also indicates that voluntary guidelines, while a positive step, are often not sufficient for comprehensive safety assurance.

Canada: Natural Health Products Regulations (NHPR)

In Canada, products akin to dietary supplements are categorized and regulated as “Natural Health Products (NHPs)”. The “Natural Health Products Regulations (NHPR)”, enacted in 2004 under the authority of the Food and Drugs Act, establish the comprehensive framework for these products.

A distinguishing feature of the Canadian system is its emphasis on pre-market review and site licensing. All NHPs must obtain a product license from Health Canada, which involves a thorough pre-market assessment for safety, efficacy, and quality [17]. Concurrently, companies involved in the packaging, manufacturing, labelling, or trade in of NHPs are required to apply for site licenses, demonstrating their adherence to Good Manufacturing Practices (GMPs) [18]. The GMP requirements for NHPs are specifically tailored to ensure product quality, encompassing standards for cleanliness, quality assurance, and meticulous record-keeping, all designed to guarantee that NHPs are effective, safe and of high quality [19].

The comprehensive pre-market scrutiny in Canada aims to foster higher consumer confidence and enable proactive risk mitigation. The mandatory pre-market product licensing, based on a review of efficacy, safety and quality, coupled with the requirement for site licenses demonstrating GMP compliance, represents a robust regulatory model [17]. This dual licensing system is explicitly designed to "ensure that Canadians have ready access to natural health products that are safe, effective and of high quality". This proactive stance reflects a recognition that the "food-like" nature of many supplements should not exempt them from rigorous health product oversight. It aims to prevent unsafe or ineffective products from entering the market in the first place, thereby reducing reliance on reactive post-market detection. Canada's regulatory framework serves as an important model for other jurisdictions seeking to enhance oversight of dietary supplements by integrating a more pharmaceutical-like pre-market assessment. This approach places the responsibility for demonstrating safety and efficacy more firmly onto manufacturers before products are widely available to the public, potentially leading to a higher standard of product quality and greater consumer trust.

South Korea: Health Functional Food Act

In South Korea, the dietary supplements are officially designated as "Health Functional Food" (HFF) and are under the regulatory purview of the “Ministry of Food and Drug Safety (MFDS)”. The MFDS is responsible for formulating policies, evaluating ingredient usage, and establishing labeling guidelines for HFFs.

A key aspect of South Korea's regulatory approach is the stringent approval process for functional ingredients. Ingredients must be recognized as "functional ingredients" by the MFDS, a determination based on robust scientific evidence. The system differentiates between "publicly notified" ingredients and "individually recognized" types, with the latter requiring specific, detailed review. HFF products must be manufactured in strict compliance with established criteria and standards, utilizing only these approved functional ingredients [4]. Regarding manufacturing and import, businesses intending to manufacture or sell HFFs must obtain permission from the MFDS for each operational site. Furthermore, import declarations are mandatory, requiring the submission of appropriate documentation to regional food and drug administrations or national quarantine services.

The centralized ingredient approval system in South Korea aims to control efficacy and safety upstream in the supply chain. By focusing on the pre-approval of functional ingredients, the MFDS seeks to control the safety and efficacy of HFFs at their very source, rather than solely relying on post-market product checks. This approach serves to minimize the risk of unproven or potentially harmful ingredients entering the market, providing a robust initial barrier against unsafe products and streamlining subsequent product approvals. This ingredient-centric regulatory model could offer a valuable strategy for other nations grappling with the challenge of regulating a diverse array of novel supplement ingredients. It effectively shifts the scientific burden of proof for functionality and safety to the ingredient level, enhancing overall product integrity and consumer trust by ensuring that the fundamental building blocks of supplements meet established safety and efficacy criteria.

Australia: TGA and Listed Medicines

In Australia, complementary medicines (CMs), which encompass dietary supplements, are regulated by the “Therapeutic Goods Administration (TGA)” under the “Therapeutic Goods Act of 1989” [3]. Australia employs a two-tiered, risk-based approach to the regulation of all medicines, including CMs. The two tiers are:

• Listed Medicines: These are generally considered lower-risk products. They must contain ingredients from a TGA-approved list of permissible ingredients and are required to be manufactured in accordance with Good Manufacturing Practice (GMP) principles [3]. Listed medicines are identified by an "Aust L" number [9]. While the safety and quality of these products are self-certified by the applicant, efficacy evidence for "assessed listed medicines" undergoes pre-market assessment by the TGA if they carry higher-risk or more definitive health claims [21].
• Registered Medicines: These are higher-risk products that require full registration with the TGA [3].

The TGA's framework integrates CMs into a broader "Therapeutic Goods" category, acknowledging their role within the healthcare system [3]. This tiered, risk-based regulation aims to balance market access with targeted oversight. By allowing self-certification for basic listed products while mandating TGA assessment for those making more definitive claims, the system attempts to streamline approval for lower-risk products while maintaining stricter control over those with higher potential impact. This approach seeks to balance market accessibility and innovation with appropriate levels of consumer protection, without imposing a full drug-like approval process on all supplements. This tiered system could offer a pragmatic solution for other countries navigating the "food versus drug" classification dilemma, providing a flexible framework that scales regulatory scrutiny based on the product's risk profile and its associated claims. This approach potentially reduces regulatory burdens for low-risk products while ensuring robust oversight for those with higher potential for harm or misleading claims, thereby optimizing resource allocation for regulatory bodies.

India: FSSAI (Food Safety and Standards Authority of India)

In India, nutraceuticals, which include dietary supplements, are regulated by the “Food Safety and Standards Authority of India (FSSAI)” under the “Food Safety and Standards Act, 2006”. The FSSAI's framework for these products is detailed in the Food Safety and Standards (“Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose and Prebiotic and Probiotic Food”) Regulations, 2022 [36]. This system distinguishes nutraceuticals as a category of "food" and not "drugs," a key difference from the drug-focused Australian model. FSSAI's regulations employ a risk-based approach, primarily focusing on pre-market approval and post-market surveillance. Key aspects of the regulations include:

• Permitted Ingredients: Products must contain ingredients from FSSAI-approved lists. The regulations specify schedules of permitted minerals, vitamins, amino acids, botanicals, and other substances [36]. This provides a clear, positive list of what is allowed in formulations.
• Good Manufacturing Practices (GMP): All manufacturing, storage, and distribution of nutraceuticals must adhere to established Good Manufacturing Practices to ensure product quality and safety [37].
• Labeling and Claims: The FSSAI has strict guidelines for labeling and advertising. Products must be clearly labeled as "Health Supplement" or "Nutraceutical" and bear the statement "NOT FOR MEDICINAL USE" unless specifically exempted^[38]. Labels are not permitted to make claims of treating, preventing, or curing a human disease. Claims must be truthful and supported by scientific data.

The FSSAI's approach is designed to ensure consumer safety and prevent misleading claims without subjecting low-risk products to the rigorous clinical trial requirements of pharmaceuticals. By creating a distinct regulatory category for nutraceuticals, India attempts to balance the need for public health protection with the promotion of a growing and innovative market. This model provides a clear alternative to the "food versus drug" debate by classifying nutraceuticals squarely within the food category, with specific regulations tailored to their unique nature and use.

Good Manufacturing Practices (GMP) are fundamental to ensuring the quality, safety, and consistency of dietary supplements. These practices provide a systematic framework that governs every aspect of the manufacturing process, from raw material sourcing to finished product release.

Core Principles of GMP/cGMP

GMP represents a comprehensive system designed to ensure that manufactured products, including foods, cosmetics, pharmaceuticals, and dietary supplements, are consistently produced and controlled according to predefined quality standards. A foundational principle of GMP is that quality cannot simply be "tested into" a batch of product; rather, it must be "built into each batch of product during all stages of the manufacturing process". This proactive approach emphasizes prevention over detection of defects.

The "c" in cGMP, particularly as enforced by the US FDA, signifies "current" practices. This implies a continuous commitment to the highest available quality standards through the adoption of up-to-date systems and technologies. This dynamic aspect ensures that manufacturing processes evolve with scientific and technological advancements, preventing stagnation in quality assurance.

The core components of GMP typically include:

• People: All personnel involved in manufacturing are expected to adhere strictly to established processes and regulations. Competency is non-negotiable, requiring that employees are adequately trained, qualified, and periodically re-qualified for their assigned tasks.
• Premises & Equipment: Manufacturing facilities must be designed, maintained, and cleaned appropriately to prevent contamination. This includes ensuring adequate sanitation of grounds, proper drainage, pest control, and a safe water supply. Equipment and utensils must be of appropriate design and construction, corrosion-resistant, made of non-toxic materials, and maintained to prevent contamination of components or finished products [23].
• Processes & Procedures: Formal, approved Standard Operating Procedures (SOPs) must cover every critical step of the manufacturing process. These procedures should be clearly defined and capable of achieving desired outcomes, supported by real-time deviation management [24].
• Products & Materials: This component emphasizes the full genealogy of materials, from supplier approval through incoming inspection, production, and release. It mandates clear specifications for primary materials, including raw products and other components, at every phase of production.
• Data Integrity & Documentation: Accurate and complete records are paramount. This involves adhering to ALCOA+ principles (Attributable, Legible, Contemporaneous, Original/Accurate, plus Complete, Consistent, Enduring, and Available) to ensure the reliability and trustworthiness of all documentation [25].

Raw Material Sourcing and Specifications

The quality of a dietary supplement begins with its raw materials. GMP emphasizes the critical importance of establishing and adhering to stringent specifications for all incoming ingredients and components. These specifications must address identity, purity, strength, and composition.

Supplier qualification is a vital part of this process. Manufacturers are required to qualify their raw material suppliers, often through auditing their facilities, to ensure they meet established quality standards [26]. This involves verifying the Certificate of Analysis (CoA) provided by suppliers through proper in-house testing to eliminate the risk of contamination or fraud along the supply chain [26]. For botanical ingredients, authenticity validation is particularly crucial, encompassing traceability information (geographic origin, cultivation, preparation), taxonomical and morphological identity, and phytochemical composition. The identification of reference standards and appropriate analytical methods for the thousands of bioactive ingredients in dietary supplements remains a challenge, with ongoing discussions about who bears the responsibility for their development [27].

Production and Process Controls

A robust production and process control system is essential for ensuring consistent product quality and preventing contamination. This involves designing processes to minimize risks and implementing rigorous controls at every stage of manufacturing. Key aspects include:

• Sanitation and Hygiene: Maintaining appropriate manufacturing conditions, including temperature and humidity control, and ensuring proper hygiene and sanitation of facilities and equipment.
• Cross-Contamination Prevention: Implementing measures to prevent cross-contamination between different products or ingredients, a common issue in multi-product facilities.
• In-Process Controls: Monitoring and controlling critical process parameters (CPPs) throughout production to ensure that the product consistently meets specifications.
• Documentation and Record-Keeping: Maintaining comprehensive records of every step in the manufacturing process, including master manufacturing records and batch production records, to ensure traceability and accountability. This includes records for water quality, equipment maintenance, and deviations [23].

Finished Product Testing and Release

Before a dietary supplement can be released to the market, it must undergo thorough testing to confirm its quality, safety, and compliance with label claims.

• Analytical Methods for Quality and Quantity Control: A variety of analytical techniques are employed to verify the identity, potency, purity, and composition of finished products. High-performance liquid chromatography (HPLC) is a frequently preferred method due to its range, accuracy, and speed for qualitative and quantitative analysis of ingredients like amino acids [28]. Testing for dietary supplements is a challenging task, often involving complex matrices and various dosage forms. Manufacturers have flexibility in choosing tests and methods, but they must be appropriate and scientifically valid [29].
• Stability Testing: Products must undergo stability testing to ensure they meet label claims through their expiration date.
• Contaminant Testing: Rigorous testing is required to detect and limit contaminants such as heavy metals (e.g., lead, arsenic, mercury, and cadmium), pesticides, microbial contaminants, and residual solvents.
• Product Specifications: Finished products must meet established specifications for identity, purity, strength, and composition. Products that do not meet these specifications are considered violative [29].

Despite the existence of regulatory frameworks and GMP guidelines, the dietary supplement industry faces significant and persistent challenges related to product quality and safety. These issues undermine consumer trust and pose considerable public health risks.

1. Adulteration and Contamination

Adulteration and contamination represent critical threats to dietary supplement quality. Adulteration often involves the intentional addition of undeclared or illegal substances, frequently for economic gain or to boost perceived efficacy. This is particularly prevalent in categories such as athletic performance, sexual enhancement, and weight loss products, where synthetic drugs (e.g., sibutramine, phosphodiesterase-5 inhibitors, stimulants) are deliberately added to confuse analytical techniques or mimic desired effects. Such practices pose serious health risks, especially for consumers with pre-existing conditions or those taking other medications, as these undeclared ingredients can interfere with prescription drugs or cause adverse events.

Beyond intentional spiking, contamination can occur through various means. This includes the presence of impurities and contaminants in excess of acceptable levels, such as heavy metals (e.g., lead, arsenic, mercury, cadmium), pesticides, and microbial contaminants. One study found microbial contamination ranging from low to high levels in a significant portion of tested dietary supplements [29]. Misidentification or substitution of botanical ingredients is another common problem, where lower-cost or incorrect plant species are used, sometimes leading to toxicity (e.g., Digitalis lanata mistaken for "plantain" leading to cardiac symptoms, or Asian Actaea species replacing American black cohosh causing liver toxicity). This economic fraud undermines product integrity and puts reputable manufacturers at a competitive disadvantage [30].

B. Regulatory Gaps and Enforcement Issues

The global dietary supplement market is characterized by a lack of global consensus on product definitions, leading to varied regulatory approaches and persistent challenges [2]. This fragmentation creates a "grey zone" between food supplements and medicines, where products may be classified differently across jurisdictions, complicating international trade and consumer understanding [6]. A significant regulatory gap exists in the US, where the FDA primarily relies on post-market surveillance. Unlike drugs, dietary supplements do not undergo pre-market review for safety and efficacy, and manufacturers are not required to submit evidence to substantiate their claims [8]. The FDA must prove a product is unsafe to remove it from the market, which can be a lengthy process, leaving consumers exposed to risks [29]. This contrasts with countries like Canada and South Korea, which employ more robust pre-market approval systems.

Enforcement of GMPs also presents challenges. While GMPs are intended to prevent adulteration and ensure quality, manufacturer adherence is sometimes questionable. The FDA conducts random audits, and reports indicate significant cGMP non-compliance violations. For instance, a GAO undercover investigation found many imported supplements contained heavy metals, and a significant percentage of products did not meet label claims in independent lab tests. Furthermore, the underreporting and incomplete reporting of adverse events (AEs) to systems like the FDA's CAERS (CFSAN Adverse Event Reporting System) hamper effective post-market surveillance [8]. The absence of a dedicated nutrivigilance system at the EU level further highlights this gap in monitoring adverse effects [12].

C. Supply Chain Integrity and Traceability

Ensuring the integrity of the dietary supplement supply chain, from raw material sourcing to the finished product reaching the consumer, is a complex and critical challenge. The global nature of the market means supply chains are often intricate and involve multiple international actors, increasing vulnerabilities to fraud and contamination. The starting point for quality control is the raw material. However, the identification and authentication of raw materials, especially botanical extracts and blends, present particular challenges for detecting misidentification and contamination [2]. The increase in demand, coupled with price increases and supply shortages for certain ingredients, creates a fertile ground for fraudsters to sell adulterated materials [30]. Economically motivated adulteration, where lower-cost ingredients are substituted, diluted, or "fortified" with undisclosed substances, is a significant concern [30].

While GMPs require manufacturers to establish specifications for incoming ingredients and verify them, the new Food Safety Modernization Act (FSMA) in the US now mandates a Food Safety Plan (FSP) for dietary ingredient suppliers, requiring them to address potential food safety hazards and manage them through a verified supply chain control program [31]. This aims to improve supply chain integrity by linking ingredients from the source to finished products [31]. However, the complexity of global supply chains and the varying regulatory requirements across countries make comprehensive traceability difficult [32]. The lack of a coherent analytical system for standardization of food additives also contributes to this challenge [28].

D. Evaluating Evidence for Product Claims

The evaluation of evidence supporting dietary supplement product claims is a contentious area, contributing to consumer confusion and regulatory challenges. As the market has grown, so has the diversity of scientific evidence, often leading to conflicting findings [2]. A significant issue is how to evaluate traditional evidence within the framework of conventional evidence-based medicine, especially when findings from traditional healing are not supported by more conventional evaluation mechanisms [2].

In the US, while claims can describe how a nutrient affects the body's structure or function, manufacturers are not required to submit evidence to the FDA to substantiate these claims [8]. This contrasts with the EU, where health claims must be scientifically substantiated and approved by the European Commission after EFSA's scientific review. Japan also requires systematic review or clinical trials for Foods with Function Claims (FFCs) and Foods for Specified Health Uses (FOSHUs) [15]. The variability in quality specifications among comparable products from different manufacturers, due to manufacturers' flexibility in choosing tests and methods, further contributes to a lack of consistency and transparency in product quality [29]. Misleading advertising practices and unproven health claims are prevalent, particularly in Europe, where some claims do not align with authorized lists or scientific evidence [33]. This situation highlights the difficulty for consumers to make informed choices and the ongoing challenge for regulators to ensure that product information is accurate and not misleading.